Betaine and nonalcoholic steatohepatitis: Back to the future?

Sandeep Mukherjee

doi:10.3748/wjg.v17.i32.3663

Betaine and nonalcoholic steatohepatitis: Back to the future?

Sandeep Mukherjee

Research output: Contribution to journal › Article

10 Scopus citations

Abstract

Nonalcoholic steatohepatitis (NASH) is an important indication for liver transplantation in many Western countries. Obesity and insulin resistance are the two most common risk factors for NASH, which can lead to recurrent NASH after liver transplantation. There is currently no approved therapy for NASH, and treatment is directed at risk factor modifcation and lifestyle changes. Betaine has been used for NASH, with mixed results, and may show promise in conjunction with other agents in clinical trials.

Original language	English (US)
Pages (from-to)	3663-3664
Number of pages	2
Journal	World Journal of Gastroenterology
Volume	17
Issue number	32
DOIs	https://doi.org/10.3748/wjg.v17.i32.3663
State	Published - Aug 28 2011
Externally published	Yes

All Science Journal Classification (ASJC) codes

Gastroenterology

Access to Document

10.3748/wjg.v17.i32.3663

Fingerprint Dive into the research topics of 'Betaine and nonalcoholic steatohepatitis: Back to the future?'. Together they form a unique fingerprint.

Cite this

Mukherjee, S. (2011). Betaine and nonalcoholic steatohepatitis: Back to the future? World Journal of Gastroenterology, 17(32), 3663-3664. https://doi.org/10.3748/wjg.v17.i32.3663

@article{bbc1ecdc154d4278baa982f4e07bd48f,

title = "Betaine and nonalcoholic steatohepatitis: Back to the future?",

abstract = "Nonalcoholic steatohepatitis (NASH) is an important indication for liver transplantation in many Western countries. Obesity and insulin resistance are the two most common risk factors for NASH, which can lead to recurrent NASH after liver transplantation. There is currently no approved therapy for NASH, and treatment is directed at risk factor modifcation and lifestyle changes. Betaine has been used for NASH, with mixed results, and may show promise in conjunction with other agents in clinical trials.",

author = "Sandeep Mukherjee",

year = "2011",

month = aug,

day = "28",

doi = "10.3748/wjg.v17.i32.3663",

language = "English (US)",

volume = "17",

pages = "3663--3664",

journal = "World Journal of Gastroenterology",

issn = "1007-9327",

publisher = "WJG Press",

number = "32",

}

TY - JOUR

T1 - Betaine and nonalcoholic steatohepatitis

T2 - Back to the future?

AU - Mukherjee, Sandeep

PY - 2011/8/28

Y1 - 2011/8/28

N2 - Nonalcoholic steatohepatitis (NASH) is an important indication for liver transplantation in many Western countries. Obesity and insulin resistance are the two most common risk factors for NASH, which can lead to recurrent NASH after liver transplantation. There is currently no approved therapy for NASH, and treatment is directed at risk factor modifcation and lifestyle changes. Betaine has been used for NASH, with mixed results, and may show promise in conjunction with other agents in clinical trials.

AB - Nonalcoholic steatohepatitis (NASH) is an important indication for liver transplantation in many Western countries. Obesity and insulin resistance are the two most common risk factors for NASH, which can lead to recurrent NASH after liver transplantation. There is currently no approved therapy for NASH, and treatment is directed at risk factor modifcation and lifestyle changes. Betaine has been used for NASH, with mixed results, and may show promise in conjunction with other agents in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=80053910713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053910713&partnerID=8YFLogxK

U2 - 10.3748/wjg.v17.i32.3663

DO - 10.3748/wjg.v17.i32.3663

M3 - Article

C2 - 21990946

AN - SCOPUS:80053910713

VL - 17

SP - 3663

EP - 3664

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 32

ER -